2009
Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection
Yilmaz A, Gisslén M, Spudich S, Lee E, Jayewardene A, Aweeka F, Price RW. Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection. PLOS ONE 2009, 4: e6877. PMID: 19721718, PMCID: PMC2731205, DOI: 10.1371/journal.pone.0006877.Peer-Reviewed Original ResearchConceptsHIV-1 infectionRaltegravir concentrationsCerebrospinal fluidTreatment-experienced HIV-1-infected patientsSystemic HIV-1 infectionHIV-1-infected patientsHIV-1-infected individualsIntegrase inhibitorsCentral nervous system penetrationAntiretroviral treatment regimensDrug entryPlasma albumin ratioCerebrospinal fluid concentrationsBlood-CSF barrierCSF albumin concentrationPlasma raltegravir concentrationsTreatment regimensAlbumin ratioDrug classesCSF specimensHIV-1CSF samplesAlbumin concentrationFluid concentrationsLiquid chromatography-tandem mass spectrometry
2008
Enfuvirtide Cerebrospinal Fluid (CSF) Pharmacokinetics and Potential use in Defining CSF HIV-1 Origin
Price RW, Parham R, Kroll JL, Wring SA, Baker B, Sailstad J, Hoh R, Liegler T, Spudich S, Kuritzkes DR, Deeks SG. Enfuvirtide Cerebrospinal Fluid (CSF) Pharmacokinetics and Potential use in Defining CSF HIV-1 Origin. Antiviral Therapy 2008, 13: 369-374. PMID: 18572749, PMCID: PMC2699482, DOI: 10.1177/135965350801300312.Peer-Reviewed Original ResearchConceptsCentral nervous systemCerebrospinal fluidCSF samplesCSF HIV-1 RNAHIV-1-infected individualsHIV-negative individualsCerebrospinal fluid pharmacokineticsHIV-1 RNAHuman central nervous systemPlasma samplesHIV-1 replicationCNS drug exposureHIV-1 quasispeciesUse of enfuvirtideResistance-associated mutationsLocal therapeutic effectCNS virusV38A mutationGp41 coding regionCSF pharmacokineticsDrug exposurePlasma concentrationsTherapeutic effectNervous systemClinical setting